Results
Seventy-four patients were randomized to ILIT with three doses of 0.1 ml of birch- and 5-grass pollen allergen extracts, or either and placebo at monthly intervals. One patient withdrew consent after the first injections and one was lost to follow-up after two injections. Seventy-two patients received all injections (Fig. 1). One patient was lost to follow-up two years after treatment; RQLQ and RTSS had been halved and the patient had not required or used anti-allergic medication. Another patient was lost to follow-up three years after ILIT and two years after treatment showed no improvement in RTSS, MS or RQLQ. Hence, 70 patients remained for analyses three years after treatment.